Investigational drug · Phase 3
Afimetoran
Also called: BMS-986256, BLN-256
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Afimetoran"
First trial start
2021
Oct 11, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Afimetoran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
- Cutaneous Lupus Erythematosus (CLE)
- Systematic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Afimetoran" as an intervention, largest first.
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusPivotal-lookingRecruiting
Beeline Medicines CorporationIndustry
NCT07881120 · 390 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 2030
Drug: Afimetoran; Placebo · For: Cutaneous Lupus Erythematosus (CLE); Systematic Lupus Erythematosus
Sites: San Diego, California; DeBary, Florida; Missoula, Montana
- A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Pivotal-lookingActive, not recruiting
Beeline Medicines CorporationIndustry
NCT04895696 · 248 participants · Start Oct 11, 2021 · Primary completion Jun 12, 2026
Drug: Afimetoran · For: Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Huntington Beach, California; La Jolla, California · 147 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05901714 · 65 participants · Start Jun 14, 2023 · Primary completion Apr 11, 2024
Drug: Afimetoran; Phenytoin and 1 more · For: Healthy Participants
Sites: Miami, Florida
- A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy ParticipantsCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05866627 · 32 participants · Start Jul 4, 2023 · Primary completion Sep 29, 2023
Drug: Famotidine; Afimetoran · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Development of Kilogram-Scale Electrochemical Ni-Catalyzed Cross Electrophile Coupling in Flow.
Kelly M, Cardinale L, Sackett KV, et al. · Org Process Res Dev 2026
- Structural and immunological impacts of TOLLIP nsSNPs: A computational biology approach to drug discovery and immune system modulation.
Habib O, Ishaq S, Habib K, et al. · PLoS One 2025
- Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll-Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study.
Hosein F, Ignatenko S, Chadwick KD, et al. · ACR Open Rheumatol 2025
- Phenoxythiazoline (FTz)-Cobalt(II) Precatalysts Enable C(sp2 )-C(sp3 ) Bond-Formation for Key Intermediates in the Synthesis of Toll-like Receptor 7/8 Antagonists.
Mills LR, Di Mare F, Gygi D, et al. · Angew Chem Int Ed Engl 2023
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.